PMID- 18777458
OWN - NLM
STAT- MEDLINE
DCOM- 20081205
LR  - 20131121
IS  - 0947-7349 (Print)
IS  - 0947-7349 (Linking)
VI  - 116 Suppl 1
DP  - 2008 Sep
TI  - Association of impaired glucose metabolism in morbid obesity with 
      hypoadiponectinaemia.
PG  - S64-9
LID - 10.1055/s-2008-1081490 [doi]
AB  - BACKGROUND: Increased circulating levels of cytokines and chemokines and 
      decreased adiponectin levels are associated with impaired glucose tolerance (IGT) 
      and type 2 diabetes mellitus (T2DM). As obesity is the major risk factor for T2DM 
      it is not clear why many patients with morbid obesity remain normoglycaemic and 
      if this protection can be attributed to a lower grade of inflammation or higher 
      adiponectin levels. MATERIALS AND METHODS: Glucose tolerance of morbidly obese 
      patients (n=2 754, body mass index > or =40 kg/m2) was assessed by oral glucose 
      tolerance tests. In a case-control design we compared levels of eight immune 
      mediators and adiponectin from patients with IGT/T2DM (n=52) and normal glucose 
      tolerance (NGT; n=59). Gene expression in peripheral blood was determined by 
      quantitative RT-PCR, and serum concentrations of immune mediators and adiponectin 
      were measured by ELISA and bead-based multiplex technology. RESULTS: About 54% of 
      the patients in our morbidly obese cohort were normoglycaemic, while 14% were 
      diagnosed with IGT and 32% with T2DM. There was no statistically significant 
      difference in mRNA expression or serum levels of proinflammatory markers. 
      Interestingly, we could demonstrate an association of NGT with higher adiponectin 
      levels (p=0.039). Adiponectin levels were negatively correlated with interleukin 
      (IL)-6 and macrophage chemoattractant protein (MCP)-1, but independent the other 
      immune mediators. CONCLUSIONS: We found an association of lower adiponectin 
      levels with IGT/T2DM, but no further increase in inflammatory markers in morbid 
      obesity. This suggests that in addition to chronic, low-grade inflammation, 
      adiponectin is an important factor in the development of, or protection against, 
      T2DM in obesity.
FAU - Schinner, S
AU  - Schinner S
AD  - Department of Endocrinology, Diabetes and Rheumatology, University Hospital 
      Dusseldorf, Germany. sven.schinner@uni-duesseldorf.de
FAU - Kempf, K
AU  - Kempf K
FAU - Overmann, H
AU  - Overmann H
FAU - Willenberg, H S
AU  - Willenberg HS
FAU - Schott, M
AU  - Schott M
FAU - Rose, B
AU  - Rose B
FAU - Scherbaum, W A
AU  - Scherbaum WA
FAU - Herder, C
AU  - Herder C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080905
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German 
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
RN  - 0 (Adiponectin)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-6)
RN  - 0 (RNA, Messenger)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adiponectin/*blood/genetics/metabolism
MH  - Adult
MH  - Case-Control Studies
MH  - Chemokine CCL2/genetics/metabolism
MH  - Cohort Studies
MH  - Cytokines/genetics/metabolism
MH  - Diabetes Mellitus, Type 2/blood/complications/genetics/metabolism
MH  - Female
MH  - Glucose/metabolism
MH  - Glucose Intolerance/blood/*complications/genetics/immunology
MH  - Humans
MH  - Interleukin-6/genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Obesity, Morbid/blood/*complications/genetics/immunology
MH  - RNA, Messenger/metabolism
EDAT- 2008/10/23 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/10/23 09:00
PHST- 2008/10/23 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/10/23 09:00 [entrez]
AID - 10.1055/s-2008-1081490 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2008 Sep;116 Suppl 1:S64-9. doi: 
      10.1055/s-2008-1081490. Epub 2008 Sep 5.